A Director at Luminex (NASDAQ: LMNX) is Selling SharesBy Carrie Williams
In addition to Kevin M. McNamara, 4 other LMNX executives reported Sell trades in the last month. This is McNamara’s first Sell trade following 3 Buy transactions.
Based on Luminex’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $71.22 million and quarterly net profit of $2.75 million. In comparison, last year the company earned revenue of $60.6 million and had a net profit of $6.4 million. The company has a one year high of $23.75 and a one year low of $17.29. LMNX’s market cap is $897.3M and the company has a P/E ratio of 24.15.
Three different firms, including Cowen & Co. and J.P. Morgan, currently also have a Sell rating on the stock.
In the last 30 days, insiders have sold $252.4K worth of LMNX shares and purchased $109.3K worth of LMNX shares. The insider sentiment on Luminex has been positive according to 24 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Luminex was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX.